Will the recent publication of the KROG 08-06 trial change your practice in node positive breast cancer patients?

I would encourage listening to Dr. @Dr. First Last's ASTRO discussion of this trial.

KROG 08-06 was powered to detect a 10% DFS advantage for inclusion of the IM chain. Meanwhile, RNI trials have demonstrated a 3-5% advantage in DFS for RNI such that even if irradiation of the IM chain were responsib...

We always try to include IMN as part of RNI but patient anatomy, nodal burden, phenotype, dose to heart, and lung dose also drive an eventual decision. Although unplanned analysis in KROG since benefit was seen in inner and central quadrant disease, would try to include more in that quadrant disease...